ALNYLAM PHARMACEUTICALS, INC. Net Income (Loss) Attributable to Parent, Diluted
ALNYLAM PHARMACEUTICALS, INC. (ALNY) reported Net Income (Loss) Attributable to Parent, Diluted of $166.89 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-07-30.
Financial Statements › Income Statement › Net Income
us-gaap:NetIncomeLossAttributableToParentDiluted · last filed 2026-07-30
- ALNYLAM PHARMACEUTICALS, INC. net income (loss) attributable to parent, diluted for the quarter ending 2026-06-30 was $166.89M.
- ALNYLAM PHARMACEUTICALS, INC. net income (loss) attributable to parent, diluted for the quarter ending 2025-12-31 was $186.42M.
- ALNYLAM PHARMACEUTICALS, INC. net income (loss) attributable to parent, diluted for the quarter ending 2025-09-30 was $252.69M.
- ALNYLAM PHARMACEUTICALS, INC. net income (loss) attributable to parent, diluted for the quarter ending 2025-06-30 was -$72.23M.
- ALNYLAM PHARMACEUTICALS, INC. net income (loss) attributable to parent, diluted for fiscal 2025 was $313.75M.
- ALNYLAM PHARMACEUTICALS, INC. net income (loss) attributable to parent, diluted for fiscal 2024 was -$278.16M.
- ALNYLAM PHARMACEUTICALS, INC. net income (loss) attributable to parent, diluted for fiscal 2023 was -$440.24M.
| Period end | Net Income (Loss) Attributable to Parent, Diluted 3 month | Net Income (Loss) Attributable to Parent, Diluted 6 month | Net Income (Loss) Attributable to Parent, Diluted 9 month | Net Income (Loss) Attributable to Parent, Diluted 12 month |
|---|---|---|---|---|
| 2026-06-30 | $166.89M 10-Q · filed 2026-07-30 | $375.25M 10-Q · filed 2026-07-30 | ||
| 2025-12-31 | $186.42M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-12 | $439.11M derived: sum of 2 quarters · filed 2026-02-12 | $366.88M derived: sum of 3 quarters · filed 2026-07-30 | $313.75M 10-K · filed 2026-02-12 |
| 2025-09-30 | $252.69M 10-Q · filed 2025-10-30 | $180.46M derived: sum of 2 quarters · filed 2026-07-30 | $127.33M 10-Q · filed 2025-10-30 | |
| 2025-06-30 | -$72.23M 10-Q · filed 2026-07-30 | -$90.48M 10-Q · filed 2026-07-30 | ||
| 2024-12-31 | -$83.76M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-12 | -$195.33M derived: sum of 2 quarters · filed 2026-02-12 | -$278.16M 10-K · filed 2026-02-12 | |
| 2024-09-30 | -$111.57M 10-Q · filed 2025-10-30 | -$194.39M 10-Q · filed 2025-10-30 | ||
| 2023-12-31 | -$137.87M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-12 | $13.41M derived: sum of 2 quarters · filed 2026-02-12 | -$440.24M 10-K · filed 2026-02-12 | |
| 2023-09-30 | $151.28M 10-Q · filed 2024-10-31 | -$302.37M 10-Q · filed 2024-10-31 | ||
| 2022-09-30 | -$405.92M 10-Q · filed 2023-11-02 | -$923.66M 10-Q · filed 2023-11-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |